Hypothalamic obesity

Endocrine Development

Volumn 17, Issue , 2009, Pages 185-196

  Hochberg, Irit ^a   Hochberg, Ze'Ev ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; CAFFEINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOMIPRAMINE; CLOZAPINE; DEXAMPHETAMINE; DOXEPIN; EPHEDRINE; IMIPRAMINE; ISOCARBOXAZID; LIOTHYRONINE; LITHIUM; MAPROTILINE; MIRTAZAPINE; NORTRIPTYLINE; OCTREOTIDE; OLANZAPINE; PAROXETINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SIBUTRAMINE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; TRIMIPRAMINE; UNINDEXED DRUG; VALPROIC ACID; ZOTEPINE;

ADIPOSE TISSUE; AUTONOMIC DYSFUNCTION; BARIATRIC SURGERY; BODY FAT; BODY WEIGHT; CANCER RADIOTHERAPY; CLINICAL FEATURE; CRANIOPHARYNGIOMA; DIET THERAPY; ENDOCRINE SYSTEM; ENERGY EXPENDITURE; ENERGY METABOLISM; ENZYME ACTIVITY; EXCISION; FOOD INTAKE; GENE MUTATION; GENETIC DISORDER; GERM CELL TUMOR; GLIOMA; HORMONAL REGULATION; HUMAN; HYPERINSULINEMIA; HYPERLEPTINEMIA; HYPERPHAGIA; HYPOPHYSIS ADENOMA; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS LESION; HYPOTHALAMUS TUMOR; IMMOBILIZATION; KINESIOTHERAPY; LIPOLYSIS; MENINGIOMA; MOLECULAR MECHANICS; MORBID OBESITY; NEUROSURGERY; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYMPATHETIC NERVE; TERATOMA; VAGUS NERVE; WEIGHT GAIN; WEIGHT REDUCTION;

HORMONES; HUMANS; HYPERPHAGIA; HYPOTHALAMIC DISEASES; HYPOTHALAMUS; OBESITY;

EID: 84925848253     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000262539     Document Type: Review

References (95)

1. Moraes JC, et al: High-fat diet induces apoptosis of hypothalamic neurons. PLoS ONE 2009;4:e5045.
2. Woods SC, DAlessio DA: Central control of body weight and appetite. J Clin Endocrinol Metab 2008; 93(11 suppl 1):S37-S50.
3. Bray GA, Gallagher TF Jr: Manifestations of hypothalamic obesity in man: a comprehensive investigation of eight patients and a reveiw of the literature. Medicine (Baltimore) 1975;54:301-330.
4. Zimmermann U, et al: Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003;37: 193-220.
5. Tong Q, et al: Synaptic release of GABA by AgRP neurons is required for normal regulation of energy balance. Nat Neurosci 2008;11:998-1000.
6. Abizaid A, et al: Ghrelin modulates the activity and synaptic input organization of midbrain dopamine neurons while promoting appetite. J Clin Invest 2006;116:3229-3239.
7. Heisler LK, et al: Serotonin reciprocally regulates melanocortin neurons to modulate food intake. Neuron 2006;51:239-249.
8. Masaki T, et al: Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity. Diabetes 2004;53:2250-2260.
9. Kim SF, et al: From the Cover: Antipsychotic druginduced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMPkinase. Proc Natl Acad Sci USA 2007;104:3456-3459.
10. Skorzewska A, et al: Abnormal food-seeking behavior after surgery for craniopharyngioma. Neuropsychobiology 1989;21:17-20.
11. Roth CL, et al: Reduced sympathetic metabolites in urine of obese patients with craniopharyngioma. Pediatr Res 2007;61:496-501.
12. Shaikh MG, Grundy RG, Kirk JM: Hyperleptinaemia rather than fasting hyperinsulinaemia is associated with obesity following hypothalamic damage in children. Eur J Endocrinol 2008;159:791-797.
13. Farooqi IS, ORahilly S: Leptin: a pivotal regulator of human energy homeostasis. Am J Clin Nutr 2009;89:980S-984S.
14. Clement K, et al: A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998;392:398-401.
15. Roth C, et al: Hyperphagia in children with craniopharyngioma is associated with hyperleptinaemia and a failure in the downregulation of appetite. Eur J Endocrinol 1998;138:89-91.
16. Guran T, et al: The role of leptin, soluble leptin receptor, resistin, and insulin secretory dynamics in the pathogenesis of hypothalamic obesity in children. Eur J Pediatr 2008.
17. Brabant G, et al: Serum leptin levels following hypothalamic surgery. Horm Metab Res 1996;28:728-731.
18. Lustig RH, et al: Hypothalamic obesity caused by cranial insult in children: altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 1999;135:162-168.
19. Bucher H, et al: Insulin-like growth factors I and II, prolactin, and insulin in 19 growth hormone-deficient children with excessive, normal, or decreased longitudinal growth after operation for craniopharyngioma. N Engl J Med 1983;309:1142-1146.
20. Frohman LA, Bernardis LL: Growth hormone and insulin levels in weanling rats with ventromedial hypothalamic lesions. Endocrinology 1968;82:1125-1132.
21. Rohner F, et al: Immediate effect of lesion of the ventromedial hypothalamic area upon glucoseinduced insulin secretion in anaesthetized rats. Diabetologia 1977;13:239-242.
22. Slaunwhite WR 3rd, Goldman JK, Bernardis LL: Sequential changes in glucose metabolism by adipose tissue and liver of rats after destruction of the ventromedial hypothalamic nuclei: effect of three dietary regimens. Metabolism 1972;21:619-631.
23. Bray GA, Inoue S, Nishizawa Y: Hypothalamic obesity. The autonomic hypothesis and the lateral hypothalamus. Diabetologia 1981(20 suppl):366-377.
24. Fan W, et al: The central melanocortin system can directly regulate serum insulin levels. Endocrinology 2000;141:3072-3079.
25. Obici S, et al: Central melanocortin receptors regulate insulin action. J Clin Invest 2001;108:1079-1085.
26. Bruning JC, et al: Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289:2122-2125.
27. Inoue S, Bray GA: The effects of subdiaphragmatic vagotomy in rats with ventromedial hypothalamic obesity. Endocrinology 1977;100:108-114.
28. Berthoud HR, Jeanrenaud B: Acute hyperinsulinemia and its reversal by vagotomy after lesions of the ventromedial hypothalamus in anesthetized rats. Endocrinology 1979;105:146-151.
29. Cox JE, Powley TL: Prior vagotomy blocks VMH obesity in pair-fed rats. Am J Physiol 1981;240: E573-E583.
30. Kiba T, et al: Ventromedial hypothalamic lesioninduced vagal hyperactivity stimulates rat pancreatic cell proliferation. Gastroenterology 1996;110: 885-893.
31. Penicaud L, et al: The autonomic nervous system, adipose tissue plasticity, and energy balance. Nutrition 2000;16:903-908.
32. Vander Tuig JG, Knehans AW, Romsos DR: Reduced sympathetic nervous system activity in rats with ventromedial hypothalamic lesions. Life Sci 1982; 30:913-920.
33. Balkan B, et al: Altered sympathetic control of nutrient mobilization during physical exercise after lesions in the VMH. Am J Physiol 1991;260: R368-R372.
34. Vander Tuig JG, Kerner J, Romsos DR: Hypothalamic obesity, brown adipose tissue, and sympathoadrenal activity in rats. Am J Physiol 1985;248:E607-E617.
35. Monda M, Sullo A, De Luca B: Lesions of the ventromedial hypothalamus reduce postingestional thermogenesis. Physiol Behav 1997;61:687-691.
36. Martins AC, et al: Adrenal medullary function and expression of catecholamine-synthesizing enzymes in mice with hypothalamic obesity. Life Sci 2004; 74:3211-3222.
37. Dun SL, et al: Cocaine- and amphetamine-regulated transcript peptide and sympatho-adrenal axis. Peptides 2006;27:1949-1955.
38. Wang C, et al: Effect of CART in the hypothalamic paraventricular nucleus on feeding and uncoupling protein gene expression. Neuroreport 2000;11:3251-3255.
39. Gullicksen PS, et al: Energy metabolism and expression of uncoupling proteins 1, 2, and 3 after 21 days of recovery from intracerebroventricular mouse leptin in rats. Physiol Behav 2002;75:473-482.
40. Haynes WG, et al: Interactions between the melanocortin system and leptin in control of sympathetic nerve traffic. Hypertension 1999;33(1 Pt 2):542-547.
41. Masuzaki H, et al: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001; 294:2166-2170.
42. Stewart PM, et al: Cortisol metabolism in human obesity: impaired cortisone-cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999;84:1022-1027.
43. Rask E, et al: Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001;86:1418-1421.
44. Draper N, et al: Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J Clin Endocrinol Metab 2002;87: 4984-4990.
45. Gelernter-Yaniv L, et al: Associations between a polymorphism in the 11 beta hydroxysteroid dehydrogenase type I gene and body composition. Int J Obes Relat Metab Disord 2003;27:983-986.
46. Friedberg M, et al: Modulation of 11 beta-hydroxysteroid dehydrogenase type 1 in mature human subcutaneous adipocytes by hypothalamic messengers. J Clin Endocrinol Metab 2003;88:385-393.
47. Lu XY: The leptin hypothesis of depression: a potential link between mood disorders and obesity? Curr Opin Pharmacol 2007;7:648-652.
48. Le Gouic S, et al: Effects of both a melatonin agonist and antagonist on seasonal changes in body mass and energy intake in the garden dormouse. Int J Obes Relat Metab Disord 1996;20:661-667.
49. Staiger H, et al: Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine betacell function. PLoS ONE 2008;3:e3962.
50. Muller HL, et al: Melatonin secretion and increased daytime sleepiness in childhood craniopharyngioma patients. J Clin Endocrinol Metab 2002;87: 3993-3996.
51. Gobatto CA, et al: The monosodium glutamate (MSG) obese rat as a model for the study of exercise in obesity. Res Commun Mol Pathol Pharmacol 2002;111:89-101.
52. de Mello MA, et al: Glucose tolerance and insulin action in monosodium glutamate (MSG) obese exercise-trained rats. Physiol Chem Phys Med NMR 2001;33:63-71.
53. Jenkins RR, Lamb DR: Effects of physical training on hypothalamic obesity in rats. Eur J Appl Physiol Occup Physiol 1982;48:355-359.
54. Haskell-Luevano C, et al: Voluntary exercise prevents the obese and diabetic metabolic syndrome of the melanocortin-4 receptor knockout mouse. Faseb J 2009;23:642-655.
55. Elias CF, et al: Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 1998;21:1375-1385.
56. del Giudice EM, et al: Mutational screening of the CART gene in obese children: identifying a mutation (Leu34Phe) associated with reduced resting energy expenditure and cosegregating with obesity phenotype in a large family. Diabetes 2001;50:2157-2160.
57. Coll AP, et al: Proopiomelanocortin and energy balance: insights from human and murine genetics. J Clin Endocrinol Metab 2004;89:2557-2562.
58. Krude H, et al: Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 1998;19: 155-157.
59. Krude H, et al: Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 2003;88:4633-4640.
60. Santoro N, et al: An insertional polymorphism of the proopiomelanocortin gene is associated with fasting insulin levels in childhood obesity. J Clin Endocrinol Metab 2004;89:4846-4849.
61. Comuzzie AG, et al: A major quantitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2. Nat Genet 1997; 15:273-276.
62. Jackson RS, et al: Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 1997;16: 303-306.
63. Farooqi IS, et al: Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 2003;348:1085-1095.
64. Lubrano-Berthelier C, et al: Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype- phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab 2006; 91:1811-1818.
65. Loos RJ, et al: Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 2008;40:768-775.
66. Xu B, et al: Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor. Nat Neurosci 2003;6:736-742.
67. Yeo GS, et al: A de novo mutation affecting human TrkB associated with severe obesity and developmental delay. Nat Neurosci 2004;7:1187-1189.
68. Yu Y, Wang Q, Huang XF: Energy-restricted pairfeeding normalizes low levels of brain-derived neurotrophic factor/tyrosine kinase B mRNA expression in the hippocampus, but not ventromedial hypothalamic nucleus, in diet-induced obese mice. Neuroscience 2009.
69. Goldstone AP, et al: Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin Endocrinol Metab 2008;93:4183-4197.
70. Cummings DE, et al: Elevated plasma ghrelin levels in Prader Willi syndrome. Nat Med 2002;8:643-644.
71. DelParigi A, et al: High circulating ghrelin: a potential cause for hyperphagia and obesity in praderwilli syndrome. J Clin Endocrinol Metab 2002;87: 5461-5464.
72. Haqq AM, et al: Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J Clin Endocrinol Metab 2003;88:174-178.
73. Eiholzer U, Blum WF, Molinari L: Body fat determined by skinfold measurements is elevated despite underweight in infants with Prader-Labhart-Willi syndrome. J Pediatr 1999;134:222-225.
74. Hoybye C, et al: Peptides associated with hyperphagia in adults with Prader-Willi syndrome before and during GH treatment. Growth Horm IGF Res 2003;13:322-327.
75. Schuster DP, Osei K, Zipf WB: Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects. Metabolism 1996;45:1514-1520.
76. Goldstone AP, et al: Fasting and postprandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J Clin Endocrinol Metab 2005;90:2681-2690.
77. Swaab DF, Purba JS, Hofman MA: Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J Clin Endocrinol Metab 1995;80:573-579.
78. Moore SJ, et al: Clinical and genetic epidemiology of Bardet-Biedl syndrome in Newfoundland: a 22-year prospective, population-based, cohort study. Am J Med Genet A 2005;132:352-360.
79. Rahmouni K, et al: Leptin resistance contributes to obesity and hypertension in mouse models of Bardet-Biedl syndrome. J Clin Invest 2008;118:1458-1467.
80. Seo S, et al: Requirement of Bardet-Biedl syndrome proteins for leptin receptor signaling. Hum Mol Genet 2009;18:1323-1331.
81. Beales PL, et al: New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. J Med Genet 1999;36:437-446.
82. Grace C, et al: Energy metabolism in Bardet-Biedl syndrome. Int J Obes Relat Metab Disord 2003; 27:1319-1324.
83. Benzinou M, et al: Bardet-Biedl syndrome gene variants are associated with both childhood and adult common obesity in French Caucasians. Diabetes 2006;55:2876-2882.
84. Holder JL Jr, Butte NF, Zinn AR: Profound obesity associated with a balanced translocation that disrupts the SIM1 gene. Hum Mol Genet 2000;9:101-108.
85. Faivre L, et al: Deletion of the SIM1 gene (6q16.2) in a patient with a Prader-Willi-like phenotype. J Med Genet 2002;39:594-596.
86. Wang JC, et al: A 5-Mb microdeletion at 6q16.- -q16.3 with SIM gene deletion and obesity. Am J Med Genet [A] 2008;146A:2975-2978.
87. Bonaglia MC, et al: Detailed phenotype-genotype study in five patients with chromosome 6q16 deletion: narrowing the critical region for Prader-Willilike phenotype. Eur J Hum Genet 2008;16: 1443-1449.
88. Michaud JL, et al: Sim1 haploinsufficiency causes hyperphagia, obesity and reduction of the paraventricular nucleus of the hypothalamus. Hum Mol Genet 2001;10:1465-1473.
89. Hung CC, et al: Studies of the SIM1 gene in relation to human obesity and obesity-related traits. Int J Obes (Lond) 2007;31:429-434.
90. Mason PW, Krawiecki N, Meacham LR: The use of dextroamphetamine to treat obesity and hyperphagia in children treated for craniopharyngioma. Arch Pediatr Adolesc Med 2002;156:887-892.
91. Ismail D, OConnell MA, Zacharin MR: Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Pediatr Endocrinol Metab 2006;19:129-134.
92. Greenway FL, Bray GA: Treatment of hypothalamic obesity with caffeine and ephedrine. Endocr Pract 2008;14:697-703.
93. Lustig RH, et al: Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2003;88:2586-2592.
94. Fernandes JK, et al: Triiodothyronine supplementation for hypothalamic obesity. Metabolism 2002;51: 1381-1383.
95. Danielsson P, et al: Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. J Clin Endocrinol Metab 2007;92:4101-4106.